Blue Chip Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$846K Buy
1,895
+204
+12% +$95.1K 0.06% 96
2025
Q4
$767K Buy
1,691
+316
+23% +$136K 0.06% 99
2025
Q3
$539K Buy
1,375
+269
+24% +$112K 0.04% 104
2025
Q2
$492K Buy
1,106
+265
+32% +$122K 0.04% 105
2025
Q1
$408K Buy
+841
New +$392K 0.04% 111
2024
Q4
Sell
-227
Closed -$106K 209
2024
Q3
$106K Hold
227
0.01% 190
2024
Q2
$106K Buy
+227
New +$98.5K 0.01% 182

Other funds holding VRTX

Blue Chip Partners's VRTX Position: Q1 2026 in Review

Blue Chip Partners increased its Vertex Pharmaceuticals (VRTX) stake by 12% in Q1 2026, buying an estimated $95.1K and bringing the position to 1,895 shares worth $846K. The position accounts for 0.06% of the portfolio, ranked #96.

Blue Chip Partners first reported a position in VRTX in Q2 2024 and has held it in 7 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Blue Chip Partners held 1,895 shares of Vertex Pharmaceuticals worth $846K as of Q1 2026.
  • Blue Chip Partners bought 204 Vertex Pharmaceuticals shares in Q1 2026, an estimated $95.1K.
  • Vertex Pharmaceuticals made up 0.06% of Blue Chip Partners's portfolio in Q1 2026, its #96 holding.
  • Blue Chip Partners first reported a position in Vertex Pharmaceuticals in Q2 2024 and has held it in 7 quarters since.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Blue Chip Partners's 13F filing for Q1 2026, filed 15 May 2026.